InspireMD opened at $0.80, in line with its previous close of $0.80. In the last trading session, the stock traded between $0.66 and $0.80. It showed a downward intraday trend.
An investment of $100 made 5 years ago in InspireMD is now worth
$ 18.63
Resulting in a loss of
$ 81.37 (81.37%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.03 (-3.13%)
Day High
$0.80
Day Low
$0.66
Day Open
$0.80
Prev Close
$0.80
Volume
1,59,035
1W Return
1.84%
1M Return
52.26%
3M Return
-8.07%
6M Return
-38.00%
1Y Return
-52.45%
Market Cap ($ Mn)
36
PE Ratio
-
PB Ratio
1.27
PEG Ratio
-
ROE
-119.58%
ROCE
-112.22%
EPS (TTM)
$-0.31
1 Week
1.84%
1 Month
52.26%
3 Months
-8.07%
6 Months
-38.00%
9 Months
-55.07%
InspireMD moves Q3 2026 earnings call to Nov 12, 4:30 pm ET
InspireMD rescheduled its Q3 2026 earnings call to November 12, 2026. New call time set for 4:30 p.m. ET, after market close. Change allows for more comprehensive business update. Webcast and phone registration available via investor portal.
YesterdayInspireMD amends warrants to raise up to $11 million for CGuard Prime launch
InspireMD amends Series J and K warrants to potentially raise $11 million. New exercise price set at $0.7674 per share, down from $1.3827 for unamended portions. Amendments align warrant exercise with anticipated Q4 2026 FDA approval for CGuard Prime 80 cm. Company targets 35,000 annual TCAR procedures in the US, doubling addressable market.
1mo agoInspireMD Q2FY26 Results: Net loss widens to $14.3M on recall impact
Net loss widened to $14.3 million in Q2 2026 from $13.2 million a year ago. Total revenue remained flat at $1.8 million despite 21% growth in international sales. Voluntary recall led to $734,000 in credits and $612,000 in inventory impairment. Company cut workforce by 20% to save $9 million annually amid cash decline. Regulatory approvals for CGuard Prime 80 targeted for Q4 2026.
1mo agoInspireMD grants 23,764 restricted shares to new employee
InspireMD granted 23,764 restricted shares to a new non-executive employee. Awards vest over three years starting in January 2027. Grants issued under Nasdaq Listing Rule 5635(c)(4). Stock issued outside the 2021 Equity Incentive Plan.
2mo agoInspireMD Q2 Results: Second Quarter 2026 Earnings Release Date Set
InspireMD, Inc. will announce its second quarter 2026 financial results on August 17, 2026, followed by a conference call at 8:30 a.m. ET. The company, which develops the CGuard Prime carotid stent system, invites investors to register for the webcast via its corporate website. This schedule allows stakeholders to review the latest data on its MicroNet mesh technology and stroke prevention outcomes.
3mo agoInspireMD approves 221,666 share inducement grant for new hire
InspireMD Inc granted 221,666 restricted stock shares to a new non-executive employee as an inducement for employment. The awards, dated August 3, 2026, vest over three years under Nasdaq Listing Rule 5635(c)(4).
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in InspireMD is now worth
$ 18.63
Resulting in a loss of
$ 81.37 (81.37%)
Note: Past profits do not guarantee future returns.
